ORA
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, ORA sits in the top decile of US sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count).
ORA: 19 sponsored US clinical trials, none currently recruiting.
ORA sponsors 19 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 18 completed. 4 of these trials are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Allergic Conjunctivitis, with 4 trials.
Top-decile sponsor footprint
ORA ranks in the top decile of sponsors by registered trial count (#772 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
18 of 19 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (94.7%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
19 total, page 1 of 1
Efficacy and Safety of PL9643 Ophthalmic Solution in Subjects With Dry Eye
NCT04268069
Study Evaluating the Efficacy and Safety of PRT-2761 for the Treatment of Acute and Chronic Allergic Conjunctivitis
NCT03320434
Visual Function Tests in Age-related Macular Degeneration
NCT03275753
Safety and Efficacy of TOP1630 for Dry Eye Syndrome
NCT03088605
Flicker Fusion Thresholds Between Young and Old Subjects at Various Luminance Levels
NCT03079570
Food Allergy Diagnostic Test Response to Previous Oral Challenge Response
NCT03693456
Food Allergy Challenge Diagnostic Study
NCT02606721
Study Evaluating Nasal Symptoms Induced by a Nasal Allergen Challenge (NAC) To House Dust Mite Allergen
NCT01936818
Mucin Levels in Dry Eye and Normal Populations
NCT05911555
Evaluation of Prednisolone in a Modified Conjunctival Allergen Challenge Model
NCT01730872
Effect of Controlled Adverse Environment (CAE) on Tear Film Stability
NCT01547936
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
NCT01534195
An Allergen BioCube (ABC) Study Evaluating the Efficacy of Fluticasone Propionate Nasal Spray Compared to Placebo
NCT01439815
A Single-Center Pilot Study to Assess Macular Function
NCT01204541
Conjunctival Allergen Challenge (CAC) Following Allergen Exposure in the Allergen BioCube (ABC)
NCT00985296
A Pilot Study Evaluating the Signs and Symptoms of Seasonal Allergic Rhinoconjunctivitis Following Exposure in the Allergen BioCube
NCT00985075
A Single-Center Evaluation of the Pattern of Allergic Signs and Symptoms During 4 Weeks in Ragweed Season
NCT00982163
Safety and Efficacy Study of a Testosterone Eye Drop for the Treatment of Meibomian Gland Dysfunction
NCT00755183
Evaluation of the Efficacy of Topical Ophthalmic Steroids in a Modified Conjunctival Allergen Challenge (CAC) Model
NCT00689078
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
| Phase 4 | 4 |
Therapeutic Areas
How the ORA archive is shaped
19 indexed studies, none listed as recruiting (0% open); 18 completed (95%).
Phase mix: 4 late (III/IV) vs 4 early (I/II) (balanced across stages).
Top condition: Allergic Conjunctivitis (4 trials), 0 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
ORA: archived-pipeline peers nationwide
Peers matched on 19 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
ORA sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 19 archived trials
- Almirall, S.A. · 19 trials · 5% recruiting
- Bastyr University · 19 trials · 11% recruiting
- Church & Dwight Company · 19 trials · 0% recruiting
- Cordis US · 19 trials · 5% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this ORA page
19 registered trials is a research-attention snapshot, not an endorsement of ORA or any single study.
- None of ORA's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Allergic Conjunctivitis is the condition ORA studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Allergic Conjunctivitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
ORA pipeline card: 19 registered trials from official public datasets.Report a data error.